Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe and United States of America (USA). The aim of this
clinical trial is to investigate the pharmacokinetics (at which rate the substance is
distributed and eliminated from the body) and the safety profile of catridecacog (recombinant
factor XIII (rFXIII)) in children with congenital FXIII A-subunit deficiency. Young children
(1 to less than 6 years old) with congenital FXIII deficiency are evaluated.